<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809939</url>
  </required_header>
  <id_info>
    <org_study_id>0129-08-MMC Ver:1</org_study_id>
    <nct_id>NCT00809939</nct_id>
  </id_info>
  <brief_title>17 Alfa Hydroxyprogesterone Caproate Versus Natural Progesterone for the Prevention of Preterm Labor</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm deliveries play a significant role in neonatal morbidity and mortality. Previous
      studies showed that administration of progesterone to pregnant women at high risk, decrease
      spontaneous preterm deliveries.

      The purpose of this study is to compare between two different modes of treatment with
      progesterone for the prevention of preterm delivery: weekly injection of 17 alfa
      hydroxyprogesterone caproate versus daily vaginal administration of progesterone in terms of
      efficacy, comfort and compliance, safety and cost of treatments.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>comfort of use and consequently of that compliance</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>previous preterm delivery, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>previous preterm delivery, treatment with daily vaginal natural progesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>short cervical length, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>short cervical length, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17 alfa hydroxyprogesterone caproate</intervention_name>
    <description>weekly injection of 250 mg until 34 weeks gestation</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>natural progesterone</intervention_name>
    <description>previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17 alfa hydroxyprogesterone caproate</intervention_name>
    <description>weekly injection, 250 mg until 34 weeks gestation</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vaginal progesterone</intervention_name>
    <description>daily vaginal progesterone 200 mg until 34 weeks gestation.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a history of spontaneous preterm delivery defined as earlier than 37
             gestational week.

          -  The subject has a short cervical length defined as 25 mm before 24 weeks gestation.

          -  A singleton gestation.

        Exclusion Criteria:

          -  Multifetal pregnancy.

          -  The subject has or will have a cervical cerclage in place.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tal Biron-Shental, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Medical Center, Israel, Affiliated to Tel Aviv University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <last_update_submitted>August 27, 2011</last_update_submitted>
  <last_update_submitted_qc>August 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>preterm delivery</keyword>
  <keyword>short cervical length</keyword>
  <keyword>progesterone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

